Plain-English translation of NCT06327269 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination approach to help prevent liver cancer from coming back after you receive a transplanted liver from a living donor. Before your transplant, you may receive advanced radiation therapy (proton therapy or yttrium-90) to shrink the tumor. After transplant, you'll take a medication called lenvatinib, which is designed to stop cancer cells from growing. The goal is to improve your chances of staying cancer-free long-term.
Liver cancer often comes back after transplant in patients with high-risk tumors, and there's currently no proven way to prevent this recurrence. Researchers believe that more aggressive tumor treatment before transplant, combined with this medication afterward, could change how the cancer behaves and significantly improve survival.
You likely qualify if…
You likely don't qualify if…
If you enroll, you may receive radiation therapy (proton or yttrium-90) before your liver transplant to help shrink your tumor. After transplant surgery, you will take the medication by mouth, along with standard anti-rejection medications. The trial will monitor you regularly to check how well the treatment works and how you tolerate it, with the goal of preventing your cancer from returning while keeping your new liver healthy.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
Taiwan